Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 3
2002 1
2003 1
2004 3
2005 4
2006 2
2007 2
2012 1
2018 1
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Improving attribution of adverse events in oncology clinical trials.
George GC, Barata PC, Campbell A, Chen A, Cortes JE, Hyman DM, Jones L, Karagiannis T, Klaar S, Le-Rademacher JG, LoRusso P, Mandrekar SJ, Merino DM, Minasian LM, Mitchell SA, Montez S, O'Connor DJ, Pettit S, Silk E, Sloan JA, Stewart M, Takimoto CH, Wong GY, Yap TA, Cleeland CS, Hong DS. George GC, et al. Among authors: klaar s. Cancer Treat Rev. 2019 Jun;76:33-40. doi: 10.1016/j.ctrv.2019.04.004. Epub 2019 Apr 25. Cancer Treat Rev. 2019. PMID: 31108240 Review.
Gene profile and response to treatment.
Smeds J, Miller LD, Bjöhle J, Hall P, Klaar S, Liu ET, Pawitan Y, Ploner A, Bergh J. Smeds J, et al. Among authors: klaar s. Ann Oncol. 2005;16 Suppl 2:ii195-202. doi: 10.1093/annonc/mdi737. Ann Oncol. 2005. PMID: 15958456 Free article. Review. No abstract available.
Changing views on adverse event reporting.
Flores B, Klaar S, O'Connor DJ. Flores B, et al. Among authors: klaar s. Lancet Haematol. 2018 Nov;5(11):e506-e507. doi: 10.1016/S2352-3026(18)30074-7. Epub 2018 Jun 12. Lancet Haematol. 2018. PMID: 29907550 No abstract available.
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.
Olivier M, Langerød A, Carrieri P, Bergh J, Klaar S, Eyfjord J, Theillet C, Rodriguez C, Lidereau R, Bièche I, Varley J, Bignon Y, Uhrhammer N, Winqvist R, Jukkola-Vuorinen A, Niederacher D, Kato S, Ishioka C, Hainaut P, Børresen-Dale AL. Olivier M, et al. Among authors: klaar s. Clin Cancer Res. 2006 Feb 15;12(4):1157-67. doi: 10.1158/1078-0432.CCR-05-1029. Clin Cancer Res. 2006. PMID: 16489069
Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts.
Pawitan Y, Bjöhle J, Amler L, Borg AL, Egyhazi S, Hall P, Han X, Holmberg L, Huang F, Klaar S, Liu ET, Miller L, Nordgren H, Ploner A, Sandelin K, Shaw PM, Smeds J, Skoog L, Wedrén S, Bergh J. Pawitan Y, et al. Among authors: klaar s. Breast Cancer Res. 2005;7(6):R953-64. doi: 10.1186/bcr1325. Epub 2005 Oct 3. Breast Cancer Res. 2005. PMID: 16280042 Free PMC article.
The European medicines agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal products for human use.
Pean E, Klaar S, Berglund EG, Salmonson T, Borregaard J, Hofland KF, Ersbøll J, Abadie E, Giuliani R, Pignatti F. Pean E, et al. Among authors: klaar s. Clin Cancer Res. 2012 Sep 1;18(17):4491-7. doi: 10.1158/1078-0432.CCR-11-3075. Epub 2012 Jul 24. Clin Cancer Res. 2012. PMID: 22829199
19 results